NCT02819596View on ClinicalTrials.gov

MEDI4736 Combinations in Metastatic Renal Cell Carcinoma

PHASE2CompletedINTERVENTIONAL

Enrollment

69

Participants

Timeline

Start Date

May 3, 2016

Primary Completion Date

July 17, 2024

Study Completion Date

July 17, 2024

Conditions

Renal Clear Cell CarcinomaRenal Papillary Cell Carcinoma

Interventions

DRUG

Savolitinib

DRUG

MEDI4736

DRUG

Tremelimumab

Trial Locations (1)

EC1M 6BQ

Thomas Powles, London

Sponsors

Collaborators (1)

All Listed Sponsors

collaborator

Vall d'Hebron Institute of Oncology

OTHER

collaborator

AstraZeneca

INDUSTRY

lead

Queen Mary University of London

OTHER